ESPR Q1 2018 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

Q1 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$0

Gross Profit

-$41M

Operating Income

-$47M

Net Income

-$46M

EPS (Diluted)

$-1.73

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$43M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$244M

Total Liabilities

$30M

Stockholders' Equity

$214M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$41M	$0	—
Operating Income	-$47M	-$41M	-14.7%
Net Income	-$46M	-$41M	-13.8%